<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244396</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10295</org_study_id>
    <nct_id>NCT04244396</nct_id>
  </id_info>
  <brief_title>Persistent Atrial Fibrillation (AF) (Asia Pacific) Observational Study</brief_title>
  <acronym>PerAF APAC</acronym>
  <official_title>Persistent AF (Asia Pacific) Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to collect safety and effectiveness data for the&#xD;
      TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC&#xD;
      patient population for the treatment of drug refractory, symptomatic persistent atrial&#xD;
      fibrillation when following standard electrophysiology mapping and radiofrequency (RF)&#xD;
      ablation procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PerAF APAC trial is a prospective, single arm, non-randomized, observational, post-market&#xD;
      clinical investigation. Approximately 100 subjects will be enrolled at up to 15 sites in&#xD;
      South Korea, Singapore, Hong Kong, Taiwan, and India. Centers in other countries within APAC&#xD;
      may be approached for participation in the clinical investigation as needed. Subjects will be&#xD;
      followed for 15-months after their initial ablation procedure. The primary effectiveness and&#xD;
      safety endpoints will be evaluated through 15-months. A core lab will independently assess&#xD;
      AF/AFL/AT recurrence via Holter monitoring at the 6-month and 15-month follow-up visits. All&#xD;
      serious adverse events (SAEs) will be independently adjudicated by qualified physicians not&#xD;
      participating in the trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of device and/or procedure-related serious adverse events</measure>
    <time_frame>7-days</time_frame>
    <description>device and/or procedure-related serious adverse events are pre-defined as below with onset within 7-days of any ablation procedure that uses the TactiCath SE catheter (initial or repeat procedure performed ≤180 days of initial procedure)&#xD;
Atrioesophageal fistula - assessed through 15 months&#xD;
Cardiac tamponade/perforation - assessed through 15 months&#xD;
Death&#xD;
Heart block&#xD;
Myocardial infarction (MI)&#xD;
Pericarditis - pleuritic symptoms &gt;7 days and/or requires hospitalization &gt;24 hrs for reasons other than observational purposes only&#xD;
Phrenic nerve injury resulting in diaphragmatic paralysis&#xD;
Pneumothorax&#xD;
Pulmonary edema (respiratory insufficiency)&#xD;
Pulmonary vein stenosis - assessed through 15 months&#xD;
Stroke/cerebrovascular accident&#xD;
Thromboembolism&#xD;
Transient ischemic attack&#xD;
Vascular access complications (including major bleeding events)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Drug refractory, symptomatic persistent atrial fibrillation</arm_group_label>
    <description>Asian population</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)</intervention_name>
    <description>TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation.</description>
    <arm_group_label>Drug refractory, symptomatic persistent atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This clinical investigation will enroll drug refractory, symptomatic, persistent atrial&#xD;
        fibrillation (AF) subjects who will undergo a de novo RF ablation procedure. Subjects must&#xD;
        provide written informed consent prior to conducting any investigation-specific procedures&#xD;
        not considered standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Documented symptomatic persistent AF, defined as continuous AF sustained &gt;7-days but&#xD;
             &lt;1 year documented by:&#xD;
&#xD;
               1. Physician's note AND one of the following:&#xD;
&#xD;
               2. 24-hr Holter showing continuous AF within 90-days of the procedure OR&#xD;
&#xD;
               3. 2 ECGs (from any form of rhythm monitoring) showing continuous AF, taken at least&#xD;
                  7-days apart&#xD;
&#xD;
          3. Refractory or intolerant to at least one Class I or III antiarrhythmic drug (AAD) as&#xD;
             evidenced by recurrent symptomatic AF NOTE: Intolerant = unable, unwilling, or refusal&#xD;
             to take AADs&#xD;
&#xD;
          4. ≥18 years of age&#xD;
&#xD;
          5. Able and willing to complete all pre-, post-, and follow-up testing and requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Continuous AF &gt;12 months (longstanding persistent AF)&#xD;
&#xD;
          2. Previous left atrial (LA) surgical or catheter ablation for AF&#xD;
&#xD;
          3. Any cardiac procedure within 90-days prior to initial procedure (Diagnostic procedures&#xD;
             with no intervention are not considered a surgical or percutaneous surgical procedure)&#xD;
&#xD;
          4. Coronary artery bypass graft (CABG) surgery within 6-months (180-days) prior to&#xD;
             initial procedure&#xD;
&#xD;
          5. Valvular cardiac surgical/percutaneous procedure (i.e. ventriculotomy, valve repair or&#xD;
             replacement and/or presence of a prosthetic or mechanical valve)&#xD;
&#xD;
          6. Any carotid stenting or endarterectomy&#xD;
&#xD;
          7. Documented or known left atrial thrombus on imaging&#xD;
&#xD;
          8. Left atrial (LA) diameter &gt;50 mm (parasternal long axis view or by CT)&#xD;
&#xD;
          9. Left Ventricular Ejection Fraction (LVEF) &lt;40%&#xD;
&#xD;
         10. Unable to take anticoagulation medication due to contraindication or intolerance&#xD;
&#xD;
         11. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
         12. Myocardial Infarction (MI), acute coronary syndrome, Percutaneous coronary&#xD;
             intervention (PCI) within the 3-months (90-days) prior to the initial procedure&#xD;
&#xD;
         13. Documented thromboembolic event (including TIA) within 12-months (365 days) prior to&#xD;
             the initial procedure&#xD;
&#xD;
         14. Rheumatic heart disease&#xD;
&#xD;
         15. Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV&#xD;
&#xD;
         16. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥&#xD;
             50%, and/or effective regurgitant orifice area ≥ 0.40cm2)&#xD;
&#xD;
         17. Awaiting cardiac transplantation or other cardiac surgery within 12-months (365 days)&#xD;
             following the initial ablation procedure&#xD;
&#xD;
         18. Unstable angina at the time of the initial procedure&#xD;
&#xD;
         19. Acute illness or active systemic infection or sepsis&#xD;
&#xD;
         20. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication,&#xD;
             major surgical procedure in the preceding 3-months, or other reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
         21. Diagnosed atrial myxoma&#xD;
&#xD;
         22. Presence of implanted implantable cardioverter defibrillator (ICD) or cardiac&#xD;
             resynchronization therapy-defibrillator (CRT-D)&#xD;
&#xD;
         23. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or&#xD;
             chronic obstructive pulmonary disease) or any other disease or malfunction of the&#xD;
             lungs or respiratory system that produces chronic symptoms&#xD;
&#xD;
         24. Significant congenital anomaly or other anatomic or comorbid medical problem that in&#xD;
             the opinion of the investigator would preclude enrollment in this study or compliance&#xD;
             with the follow-up requirements or impact the scientific soundness of the clinical&#xD;
             trial results&#xD;
&#xD;
         25. Pregnant or nursing subjects and those who plan pregnancy during the clinical&#xD;
             investigation follow-up period&#xD;
&#xD;
         26. Enrollment in an investigational study evaluating another device, biologic, or drug&#xD;
             that may interfere with this clinical investigation at the time of the initial&#xD;
             procedure or within 30 days prior to the initial procedure&#xD;
&#xD;
         27. Presence of any condition that precludes appropriate vascular access or manipulation&#xD;
             of catheter&#xD;
&#xD;
         28. Life expectancy less than 12-months&#xD;
&#xD;
         29. Body mass index &gt;40 kg/m2&#xD;
&#xD;
         30. Known sensitivity to contrast media (if needed during the procedure) that cannot be&#xD;
             controlled with pre-medication&#xD;
&#xD;
         31. Renal failure requiring dialysis&#xD;
&#xD;
         32. Presence of other medical, social, or psychological conditions that, in the&#xD;
             investigator's opinion, could limit the subject's ability to participate in the&#xD;
             clinical investigation or to comply with follow-up requirements, or impact the&#xD;
             scientific soundness of the clinical investigation results&#xD;
&#xD;
         33. History of atriotomy or ventriotomy&#xD;
&#xD;
         34. Implanted left atrial appendage occlusion device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristin Ruffner</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Jesser</last_name>
    <phone>+16517563454</phone>
    <email>emily.jesser@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin Pang Chan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sejong Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Weon Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Nam Pak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Centre</name>
      <address>
        <city>Soeul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gi-Byoung Nam</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Heart Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Keong Ching</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pipin Kojodjojo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yung-Lung Chen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Wei Lo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thoranis Chantrarat</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent Atrial Fibrillation</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Tachycardia</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Cardiac Conduction System Disease</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

